Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SANDIMMUNE vs ABLYSINOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclosporine is a calcineurin inhibitor. It binds to cyclophilin, forming a complex that inhibits calcineurin, thereby blocking the dephosphorylation and nuclear translocation of NF-AT, reducing T-cell activation and cytokine production.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death. The liposomal formulation enhances delivery to fungal cells while reducing host toxicity.
Prophylaxis of organ rejection in kidney, liver, and heart transplants,Treatment of chronic allograft rejection in kidney, liver, and heart transplants,Severe active rheumatoid arthritis (FDA-approved),Psoriasis (FDA-approved),Off-label: atopic dermatitis, nephrotic syndrome, severe ulcerative colitis, aplastic anemia
Empiric therapy for presumed fungal infection in febrile neutropenic patients,Treatment of systemic fungal infections (e.g., aspergillosis, candidiasis, cryptococcosis),Treatment of visceral leishmaniasis
Initial oral dose: 10-15 mg/kg/day divided q12h, then taper to 5-10 mg/kg/day. IV dose: 5-6 mg/kg/day continuous infusion or divided q12h.
Adults: 5 mg orally once daily, increased to 10 mg once daily after 2 weeks if tolerated, maximum 10 mg daily.
Terminal elimination half-life is approximately 8.4 hours (range 6–24 hours) in adults; prolonged in patients with hepatic impairment.
Terminal elimination half-life is 4–6 hours in patients with normal renal function; prolonged to 12–24 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism. Metabolites are excreted primarily in bile and feces.
Ivermectin is metabolized primarily by CYP3A4 to hydroxylated and demethylated metabolites. Phase II glucuronidation may occur. No active metabolites are identified.
Primarily biliary/fecal (94% of metabolites); renal elimination is minimal (<6% as unchanged drug and metabolites).
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%; the remaining 10% is metabolized.
90–98% bound, primarily to lipoproteins and albumin.
Approximately 85% bound to serum albumin and alpha-1-acid glycoprotein.
3–5 L/kg in adults; high distribution indicates extensive tissue binding, including to erythrocytes and lymphocytes.
Volume of distribution is 0.5 L/kg, indicating distribution primarily into extracellular fluid.
Oral: 30% (range 10–60%) due to extensive first-pass metabolism; IV: 100%; ophthalmic: not quantified, minimal systemic absorption.
Oral bioavailability is 40–50% due to first-pass metabolism; intramuscular bioavailability is 80%.
For Cr Cl < 30 m L/min: reduce dose by 25-50%. Monitor serum creatinine closely. Avoid in severe renal impairment unless benefit outweighs risk.
GFR ≥30 m L/min: no adjustment; GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B or C: reduce dose by 25-50%. Monitor cyclosporine levels and hepatic function.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated.
Children: 10-15 mg/kg/day oral divided q12h; IV: 5-6 mg/kg/day. Adjust based on trough levels (target 100-400 ng/m L).
Not approved for use in pediatric patients.
Start at low end of dosing range due to reduced renal and hepatic function. Monitor renal function and cyclosporine levels, as elderly are more susceptible to nephrotoxicity.
No specific dose adjustment; monitor for increased sensitivity and renal function.
Increased susceptibility to infection and possible development of lymphoma and other malignancies. Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe Sandimmune.
This drug should be used primarily for treatment of progressive, potentially life-threatening fungal infections; it is not intended for non-invasive forms of disease (e.g., oral thrush, vaginal candidiasis).
Nephrotoxicity: Monitor renal function closely; dose-dependent and may progress to chronic nephropathy.,Hepatotoxicity: Elevations in liver enzymes and bilirubin.,Hypertension: Common; may require antihypertensive therapy.,Neurotoxicity: Tremor, convulsions, headache, and other neurological effects.,Hyperkalemia: Risk increases with concurrent use of potassium-sparing diuretics or ACE inhibitors.,Hypomagnesemia: Monitor magnesium levels.,Vaccinations: Live vaccines may be less effective and should be avoided.,Carcinogenesis: Increased risk of skin cancer and lymphoproliferative disorders.
Monitor renal function closely; may cause dose-dependent nephrotoxicity. Premedicate for infusion reactions (fever, chills, rigors). Monitor electrolytes (hypokalemia, hypomagnesemia). Risk of cardiotoxicity with rapid infusion. Use caution in patients with renal impairment; dose adjustment required.
Hypersensitivity to cyclosporine or any component of the formulation,Concurrent use with PUVA or UVB therapy in psoriasis patients (increased risk of skin cancer),Uncontrolled hypertension or malignancy (relative for non-transplant indications)
Hypersensitivity to amphotericin B or any component of the formulation, unless the benefit outweighs the risk.
Avoid grapefruit and grapefruit juice. High-fat meals may reduce absorption; administer consistently with or without food. Do not take with potassium-rich foods or salt substitutes without monitoring.
Avoid grapefruit and grapefruit juice as they may increase fingolimod concentrations. No specific dietary restrictions, but maintain adequate hydration.
Cyclosporine is not a major human teratogen. First trimester exposure is not associated with an increased risk of major birth defects, but may increase the risk of preterm birth (28-33 weeks) and low birth weight. Second and third trimester use is associated with increased risk of gestational hypertension, preeclampsia, and fetal growth restriction. Prematurity and transient neonatal immunosuppression have been reported.
Category D. First trimester: increased risk of cardiac malformations (Ebstein anomaly) and neural tube defects. Second/third trimesters: fetal toxicity including oligohydramnios, premature closure of ductus arteriosus, and neonatal renal impairment.
Cyclosporine is excreted into human breast milk. The milk-to-plasma ratio (M/P) ranges from 0.17 to 1.4, with an average of approximately 0.5. The relative infant dose is estimated to be less than 2% of the maternal weight-adjusted dose. Breastfeeding is generally considered acceptable if maternal levels are maintained within therapeutic range and infant is monitored for potential adverse effects (e.g., immunosuppression).
Contraindicated. Excreted in human milk; M/P ratio not determined. Potential for serious adverse reactions in breastfed infants.
Pregnancy induces increased volume of distribution and enhanced clearance of cyclosporine, leading to decreased trough levels. Dose adjustments may be required, especially in the second and third trimesters. Increase dose as needed to maintain therapeutic trough concentrations (typically 100-400 ng/m L, depending on indication). Postpartum, dose should be reduced back to prepregnancy levels due to return of normal clearance.
Increased renal clearance in pregnancy may require dose increments of 30-50% to maintain therapeutic levels; monitor serum lithium concentrations and adjust dose to therapeutic range (0.6-1.2 m Eq/L).
Monitor trough levels 12 hours post-dose; target varies by transplant organ (e.g., 200-400 ng/m L for kidney, 250-800 ng/m L for liver early post-transplant). Adjust for hepatic dysfunction; cyclosporine is extensively metabolized by CYP3A4. Avoid live vaccines. Use with caution in renal impairment; dose reduction may be needed. Drug interactions: avoid with potassium-sparing diuretics due to hyperkalemia risk; monitor for gingival hyperplasia and hypertension.
ABLYSINOL (fingolimod) is a sphingosine-1-phosphate receptor modulator used for relapsing forms of multiple sclerosis. First-dose monitoring for bradycardia (6 hours) is mandatory; consider pre-treatment ECG. Avoid live vaccines during and for 2 months after therapy. Monitor for macular edema (ophthalmologic exam at baseline and 3-4 months). Lymphopenia is expected; check CBC before initiation and periodically. Drug interactions: QTc-prolonging agents, immunosuppressants, beta-blockers, calcium channel blockers. Do not use in patients with recent MI, unstable angina, stroke, TIA, or certain arrhythmias.
Take at the same time every day with a full glass of water, consistently with or without food.,Do not consume grapefruit or grapefruit juice; it can increase cyclosporine levels.,Report signs of infection (fever, sore throat), tremors, or changes in urine output.,Avoid live vaccines (e.g., MMR, nasal flu spray) and contact with recently vaccinated individuals.,Use sunscreen as cyclosporine may increase sensitivity to sunlight.,Do not change brand or dosage form without consulting prescriber.
Stay hydrated and avoid grapefruit juice; it may increase drug levels.,Report any vision changes, slow heartbeat, or dizziness immediately.,Avoid pregnancy; use effective contraception during and for 2 months after stopping.,Do not receive live vaccinations during treatment.,Take exactly as prescribed; do not skip doses or stop suddenly.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SANDIMMUNE vs ABLYSINOL, answered by our medical review team.
SANDIMMUNE is a Calcineurin Inhibitor that works by Cyclosporine is a calcineurin inhibitor. It binds to cyclophilin, forming a complex that inhibits calcineurin, thereby blocking the dephosphorylation and nuclear translocation of NF-AT, reducing T-cell activation and cytokine production.. ABLYSINOL is a Calcineurin inhibitor that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death. The liposomal formulation enhances delivery to fungal cells while reducing host toxicity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SANDIMMUNE and ABLYSINOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SANDIMMUNE is: Initial oral dose: 10-15 mg/kg/day divided q12h, then taper to 5-10 mg/kg/day. IV dose: 5-6 mg/kg/day continuous infusion or divided q12h.. The standard adult dose of ABLYSINOL is: Adults: 5 mg orally once daily, increased to 10 mg once daily after 2 weeks if tolerated, maximum 10 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SANDIMMUNE and ABLYSINOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SANDIMMUNE is classified as Category C. Cyclosporine is not a major human teratogen. First trimester exposure is not associated with an increased risk of major birth defects, but may increase the risk of preterm birth (2. ABLYSINOL is classified as Category C. Category D. First trimester: increased risk of cardiac malformations (Ebstein anomaly) and neural tube defects. Second/third trimesters: fetal toxicity including oligohydramnios, p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.